Incurable lung cancer could soon become treatable, according to experts conducting a world-first trial on the NHS.

The market could potentially see the emergence of new biotech industry leaders. Since the year started, Viking Therapeutics ...

AbbVie (ABBV) announced submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for accelerated ...

On September 19, the FDA handed down its third amivantamab (Rybrevant; Johnson & Johnson) approval for 2024 in non–small cell lung cancer (NSCLC), giving the third-generation tyrosine kinase inhibitor ...

Houston Methodist researchers have developed an advanced mathematical model that predicts how novel treatment combinations ...

Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...

Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.

The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...

The third-generation EGFR inhibitor will now be an option for patients whose tumors are not metastatic but can't be removed with surgery.

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo.

The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung ...